Outgoing CEO Kevin Sayer expects expanding coverage of Dexcom’s glucose sensors for people with Type 2 diabetes and ...

SAN DIEGO - Dexcom reported revenue growth of 15% year-over-year to $1.157 billion for the second quarter of 2025.

The recall affects Dexcom G6, G7, ONE, and ONE+ continuous glucose monitor receivers but not the smartphone apps or insulin ...

DexCom, Inc. DXCM reported second-quarter 2025 adjusted earnings per share (EPS) of 48 cents, which beat the Zacks Consensus ...

Medical device company DexCom (NASDAQ:DXCM) in Q2 CY2025, with sales up 15.2% year on year to $1.16 billion. The company ...

Innovations are expanding the number of people who can benefit from continuous glucose monitoring and a recent move by ...

In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections of the company’s facilities in San Diego ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 ...

With an overall MARD of 8.0%, 3 Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia and increase time in range. 4-8 ...

The FDA on March 27 permitted the marketing of the Dexcom G6 integrated continuous glucose monitoring system for diabetes patients age 2 and older. Here are four things to know about the device. 1 ...

FDA approves DexCom’s diabetes Android app: 3 things to know The Food and Drug Administration on Wednesday approved an Android version of Dexcom’s diabetes management mobile app.